News

Thermo Fisher Scientific announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical…
Read More...

Arcus Biosciences, Inc. and WuXi Biologics announced an expansion of their existing strategic relationship under which the parties will discover anti-CD39 antibodies using WuXi Bio’s…
Read More...

Amgen announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational KRASG12C inhibitor, sotorasib, for the treatment of…
Read More...

Applied BioMath announced a collaboration with Antengene Corporation for the development of a systems pharmacology modeling in immuno-oncology. Applied BioMath will develop a systems…
Read More...

Pfizer Inc. and Sangamo Therapeutics, Inc. a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or…
Read More...

Passage Bio, Inc. a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, and Catalent, the leading global…
Read More...

PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery,  announced a strategic partnership with Pfizer Inc. with the goal of…
Read More...

Cybin Inc. announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CDN$20,161,575 (approximately USD$15.75 million) in an…
Read More...

Aligos Therapeutics, Inc. announced that it has entered into an Exclusive License and Research Collaboration Agreement with Merck, known as MSD outside the United States and Canada,…
Read More...

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets…
Read More...

Bayer and Atara Biotherapeutics, Inc. announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell…
Read More...

Eli Lilly and Company and UnitedHealth Group announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals.…
Read More...

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment…
Read More...

Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix, a global biopharmaceutical company developing and commercializing rare…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with…
Read More...

Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, announces that the European Medicines Agency…
Read More...

Appili Therapeutics Inc. a biopharmaceutical company focused on anti-infective drug development, announced  that investigators have dosed the first participant in its Phase 3 trial…
Read More...

Merck KGaA, Darmstadt, Germany, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of…
Read More...

Roche announced that its Elecsys Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The serology (blood)…
Read More...

Exelixis, Inc., Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC)…
Read More...